<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lederman, Lynne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Hirano, Yuji</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Teriparatide for Patients with RA and Osteoporosis Requires More Study</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">22-22</style></pages><abstract><style  face="normal" font="default" size="100%">Early intensive treatment with methotrexate (MTX) and biologic agents is effective in rheumatoid arthritis (RA), but comorbidities, such as osteoporosis, also require treatment to reduce morbidity and improve quality of life. One treatment is daily teriparatide [European League Against Rheumatism 2014 (abstract OPO276)]. Osteoporosis in patients with RA is multifactorial; excess inflammatory cytokines, corticosteroids used to treat the disease, decreased activity due to joint pain, and postmenopausal osteoporosis are contributory factors.</style></abstract><number><style face="normal" font="default" size="100%">17</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>